FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2781305019> ?p ?o ?g. }

• W2781305019 endingPage "793" @default.
• W2781305019 startingPage "785" @default.
• W2781305019 abstract "Objective: Observational studies can provide evidence about patient outcomes in routine clinical practice. This prospective, non-interventional study (BELIEVE) is the largest real-world European study to date to assess quality-of-life, treatment satisfaction, resource utilization, and persistence in patients with overactive bladder (OAB) who were prescribed mirabegron as part of routine clinical practice.Methods: The primary objective was to evaluate change from baseline in quality-of-life based on overactive bladder questionnaire (OAB-q) sub-scales. Secondary objectives included evaluation of treatment persistence, patient satisfaction, healthcare resource utilization and adverse events (AEs). Follow-up was for 12 months with visit windows at 2–4 and 10–12 months. Median change from baseline in total OAB-q and its sub-scales (Health-related quality-of-life [HRQoL] and symptom bother scale) were assessed.Results: Overall, 862 patients were enrolled from eight European countries. In the Full Analysis Set (FAS), 73.7% were female, mean age was 61.2 years; 47.7% ≥65 years. At baseline, 41.3% had switched from other OAB treatments, 42.2% were treatment naïve, 10.1% were lapsed, and 6.4% were on combination treatment. Symptom bother and HRQoL total scores improved from baseline to 2–4 and 10–12 months. There was a notable improvement in dry rate, increasing from 34.9% at baseline to 43.7% at 10–12 months in the FAS, and a reduction in pad use. Persistence was high, with 53.8% of FAS patients remaining on mirabegron at 10–12 months. Overall, no unexpected safety issues were observed and AEs were consistent with the known safety profile of mirabegron.Conclusion: Patients receiving mirabegron in a real-world setting reported meaningful improvements in QoL and health status, with a persistence rate of 53.8% at 12 months for the FAS. No unexpected safety issues were observed, and AEs were consistent with the known safety profile of mirabegron." @default.
• W2781305019 created "2018-01-05" @default.
• W2781305019 creator A5014180789 @default.
• W2781305019 creator A5024731118 @default.
• W2781305019 creator A5033934531 @default.
• W2781305019 creator A5049416260 @default.
• W2781305019 creator A5070462882 @default.
• W2781305019 creator A5072729750 @default.
• W2781305019 creator A5072891806 @default.
• W2781305019 creator A5079692592 @default.
• W2781305019 creator A5086794947 @default.
• W2781305019 date "2018-01-10" @default.
• W2781305019 modified "2023-09-26" @default.
• W2781305019 title "Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study" @default.
• W2781305019 cites W1590256680 @default.
• W2781305019 cites W1772646200 @default.
• W2781305019 cites W1787320721 @default.
• W2781305019 cites W1979747755 @default.
• W2781305019 cites W1981353722 @default.
• W2781305019 cites W1987249698 @default.
• W2781305019 cites W1990964605 @default.
• W2781305019 cites W2014075072 @default.
• W2781305019 cites W2042153553 @default.
• W2781305019 cites W2056255004 @default.
• W2781305019 cites W2067945145 @default.
• W2781305019 cites W2074760879 @default.
• W2781305019 cites W2077126096 @default.
• W2781305019 cites W2096360296 @default.
• W2781305019 cites W2098718880 @default.
• W2781305019 cites W2107806473 @default.
• W2781305019 cites W2110991424 @default.
• W2781305019 cites W2122767178 @default.
• W2781305019 cites W2128421946 @default.
• W2781305019 cites W2144564072 @default.
• W2781305019 cites W2209565190 @default.
• W2781305019 cites W2212452621 @default.
• W2781305019 cites W2293202443 @default.
• W2781305019 cites W2312281989 @default.
• W2781305019 cites W2519995469 @default.
• W2781305019 cites W2554333722 @default.
• W2781305019 cites W2587662747 @default.
• W2781305019 cites W2606250578 @default.
• W2781305019 cites W2741709782 @default.
• W2781305019 cites W2747555826 @default.
• W2781305019 cites W2064565242 @default.
• W2781305019 doi "https://doi.org/10.1080/03007995.2017.1419170" @default.
• W2781305019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29254376" @default.
• W2781305019 hasPublicationYear "2018" @default.
• W2781305019 type Work @default.
• W2781305019 sameAs 2781305019 @default.
• W2781305019 citedByCount "18" @default.
• W2781305019 countsByYear W27813050192018 @default.
• W2781305019 countsByYear W27813050192019 @default.
• W2781305019 countsByYear W27813050192020 @default.
• W2781305019 countsByYear W27813050192021 @default.
• W2781305019 countsByYear W27813050192022 @default.
• W2781305019 countsByYear W27813050192023 @default.
• W2781305019 crossrefType "journal-article" @default.
• W2781305019 hasAuthorship W2781305019A5014180789 @default.
• W2781305019 hasAuthorship W2781305019A5024731118 @default.
• W2781305019 hasAuthorship W2781305019A5033934531 @default.
• W2781305019 hasAuthorship W2781305019A5049416260 @default.
• W2781305019 hasAuthorship W2781305019A5070462882 @default.
• W2781305019 hasAuthorship W2781305019A5072729750 @default.
• W2781305019 hasAuthorship W2781305019A5072891806 @default.
• W2781305019 hasAuthorship W2781305019A5079692592 @default.
• W2781305019 hasAuthorship W2781305019A5086794947 @default.
• W2781305019 hasBestOaLocation W27813050192 @default.
• W2781305019 hasConcept C126322002 @default.
• W2781305019 hasConcept C141071460 @default.
• W2781305019 hasConcept C142724271 @default.
• W2781305019 hasConcept C159110408 @default.
• W2781305019 hasConcept C1862650 @default.
• W2781305019 hasConcept C197934379 @default.
• W2781305019 hasConcept C204787440 @default.
• W2781305019 hasConcept C23131810 @default.
• W2781305019 hasConcept C2775944032 @default.
• W2781305019 hasConcept C2778164427 @default.
• W2781305019 hasConcept C2778941218 @default.
• W2781305019 hasConcept C2779951463 @default.
• W2781305019 hasConcept C71924100 @default.
• W2781305019 hasConceptScore W2781305019C126322002 @default.
• W2781305019 hasConceptScore W2781305019C141071460 @default.
• W2781305019 hasConceptScore W2781305019C142724271 @default.
• W2781305019 hasConceptScore W2781305019C159110408 @default.
• W2781305019 hasConceptScore W2781305019C1862650 @default.
• W2781305019 hasConceptScore W2781305019C197934379 @default.
• W2781305019 hasConceptScore W2781305019C204787440 @default.
• W2781305019 hasConceptScore W2781305019C23131810 @default.
• W2781305019 hasConceptScore W2781305019C2775944032 @default.
• W2781305019 hasConceptScore W2781305019C2778164427 @default.
• W2781305019 hasConceptScore W2781305019C2778941218 @default.
• W2781305019 hasConceptScore W2781305019C2779951463 @default.
• W2781305019 hasConceptScore W2781305019C71924100 @default.
• W2781305019 hasIssue "5" @default.
• W2781305019 hasLocation W27813050191 @default.
• W2781305019 hasLocation W27813050192 @default.
• W2781305019 hasLocation W27813050193 @default.

• next